Hepatocellular carcinoma, the most common form of liver cancer, is notorious for its silent progression. Global cancer statistics from 2018 ranked liver cancer as the sixth most common malignancy and the fourth leading cause of cancer death worldwide. Because most patients are diagnosed only after the disease has reached intermediate or advanced stages, surgical resection is often no longer an option. For these individuals, treatment relies on non-curative approaches such as chemotherapy, targeted drug therapy, and immunotherapy, making any improvement in the effectiveness of these tools a matter of life and death.

Tyrosine kinase inhibitors, or TKIs, form the backbone of pharmacological treatment for advanced liver cancer. First-line drugs such as sorafenib and lenvatinib block the signaling pathways that tumor cells use to proliferate and survive, but many patients eventually progress or develop resistance. Regorafenib, approved by the U.S. Food and Drug Administration in 2017 for patients whose disease advances on sorafenib, targets a broad panel of receptors including VEGFR1-3, PDGFR-beta, KIT, RET, and RAF, and uniquely also hits fibroblast growth factor receptors and the angiopoietin 1 receptor known as TIE2. Preclinical work has suggested regorafenib is pharmacologically more potent than sorafenib, capable of blocking angiogenesis, tumorigenesis, and metastasis while also modulating tumor immunity. Earlier studies showed it can drive liver cancer cells into apoptosis by directly activating the phosphatase SHP-1, which suppresses phosphorylated STAT3, an effect independent of its anti-angiogenic activity.

On the immunotherapy side, the team turned to BMS-1, a small molecule first described in a 2015 patent filed by Bristol-Myers Squibb as part of a series of compounds that disrupt the interaction between the immune checkpoint proteins PD-1 and PD-L1. Antibody drugs such as atezolizumab and avelumab have shown promise against several malignancies, but antibodies suffer from drawbacks including immunogenicity and poor penetration of tumor tissue, which contribute to low response rates in some patients. Small-molecule checkpoint inhibitors could, in principle, sidestep these limitations, and combining them with other agents has become an active research frontier.

To test whether BMS-1 truly engages its intended target, the researchers first ran molecular docking simulations using AutoDock Vina software. The predicted binding energy of the BMS-1-PD-L1 complex was a favorable minus 11.633 kilocalories per mole, and the structural model placed BMS-1 wedged between PD-L1 dimers, consistent with the idea that the compound prevents the ligand from engaging PD-1 on T cells. The team then measured how effectively each drug killed three human hepatocellular carcinoma cell lines, SMMC-7721, Hep3B, and SK-Hep1, using CCK-8 viability assays. The half-maximal inhibitory concentrations came out at roughly 13.35, 13.32, and 9.50 micromolar for regorafenib, and 74.11, 73.08, and 53.76 micromolar for BMS-1 across the three lines, establishing dose ranges for combination testing.

When the drugs were combined at concentrations below each one’s IC50, the results were striking. Using CompuSyn software to calculate combination indices, the team found values below 1, the mathematical signature of synergy rather than simple additivity, in SMMC-7721 cells across the tested combinations, and in Hep3B and SK-Hep1 cells for most combinations. The pairing of 6 micromolar regorafenib with 30 micromolar BMS-1 showed synergy in all three cell lines and was selected for deeper analysis. Transwell assays added another dimension: regorafenib alone significantly curbed the migration and invasion of the cancer cells, BMS-1 alone had little effect, and the combination suppressed these malignant behaviors even more strongly than regorafenib by itself.

Digging into the mechanism, the researchers tracked how the drug pair altered cell cycle machinery. EdU incorporation assays revealed a sharp drop in the fraction of cells in S phase after combination treatment, and western blotting showed that levels of Cyclin A2, Cyclin B1, Cyclin D1, and Cyclin D3, the proteins that drive cells through the G1/S and G2/M checkpoints, were downregulated, with Cyclin A2 and Cyclin B1 significantly lower in the combination group than with either drug alone. Apoptosis assays told a parallel story. Flow cytometry with Annexin V and propidium iodide staining, backed up by TUNEL staining, showed that the combination produced the highest rate of late apoptosis in all three cell lines, while western blots revealed a marked increase in cleaved PARP, a canonical executioner of programmed cell death, and a decrease in the proliferation marker PCNA.

One of the most intriguing findings emerged when the team introduced immune cells into the picture. Hepatocellular carcinoma cells barely expressed PD-L1 when grown alone, but when the researchers co-cultured them with peripheral blood mononuclear cells isolated from healthy volunteers, PD-L1 expression surged, mimicking the immune pressure of a real tumor microenvironment. Under those conditions, regorafenib pushed PD-L1 levels down, BMS-1 had a modest effect, and the combination drove PD-L1 expression down significantly. The authors speculate that regorafenib’s shared target FGFR4, which lenvatinib uses to promote proteasomal degradation of PD-L1 through the FGFR4-glycogen synthase kinase 3-beta pathway, may underlie this effect, though they caution that the exact mechanism remains unproven.

The combination also held up in living animals. In nude mice bearing subcutaneous tumors derived from SMMC-7721 cells, four weeks of treatment with intraperitoneal BMS-1 at 20 milligrams per kilogram twice weekly plus oral regorafenib at 5 milligrams per kilogram five times weekly shrank tumor volume and weight more dramatically than either drug alone. The authors are careful to note the caveats: the xenograft model lacks a fully functional immune system, so the immunological component of the synergy could not be fully assessed, and systemic tolerability has yet to be evaluated prospectively. They also point to related work suggesting that BMS-series compounds and other biphenyl derivatives can trigger cancer cell death through non-immune pathways, such as inhibition of AKT phosphorylation or modulation of TGF-beta/Smad signaling, hinting that BMS-1 may be doing double duty.

Even so, the study adds momentum to one of the hottest ideas in oncology: that molecularly targeted drugs can remodel the tumor microenvironment in ways that make immune checkpoint blockade work better. Prior research has shown that regorafenib can boost CD8-positive T cell activation by blocking interferon-gamma-induced PD-L1 expression in melanoma, and that combining kinase inhibitors with checkpoint inhibitors can allow cytotoxic T lymphocytes to infiltrate tumors more effectively. With single-agent checkpoint inhibitors such as nivolumab and pembrolizumab delivering median overall survival of only 15.6 and 12.9 months in liver cancer trials, respectively, the need for better combinations is acute. If future studies in immunocompetent models and eventually patients confirm what the cell cultures and mouse xenografts suggest, the regorafenib-BMS-1 pairing could provide a theoretical foundation for a new generation of chemo-immunotherapy against hepatocellular carcinoma, one in which a kinase inhibitor and a checkpoint blocker amplify each other’s strengths while keeping doses, and side effects, in check.

Subject of Research: Combination therapy with regorafenib and the small-molecule PD-1/PD-L1 inhibitor BMS-1 for hepatocellular carcinoma

Article Title: BMS-1 synergistically promotes the anti-tumor effect of regorafenib on hepatocellular carcinoma

Article References: Yu, G., Li, J., Wang, K., Fu, F., Lin, J., Xu, W., Liu, S., & Yang, H. (2026). BMS-1 synergistically promotes the anti-tumor effect of regorafenib on hepatocellular carcinoma. Heliyon, 12(15), Article e45420. https://doi.org/10.1016/j.heliyon.2026.e45420

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45420

Keywords: hepatocellular carcinoma, regorafenib, BMS-1, PD-1/PD-L1 inhibitors, tyrosine kinase inhibitors, immunotherapy, combination therapy, apoptosis, cell cycle, tumor microenvironment, xenograft model, synergy

A systematic review and meta-analysis spearheaded by Liu, Shang, Gao, and colleagues rigorously examined the therapeutic potential of PD-1/PD-L1 inhibitors in conjunction with CRT for patients with LA-NPC. The research team synthesized data from randomized controlled trials (RCTs) up to March 2025, scrutinizing both efficacy and safety outcomes to draw a comprehensive picture of this evolving treatment landscape.

The meta-analysis incorporated two high-quality RCTs encompassing a total of 575 patients. This relatively modest dataset nonetheless provided critical insights into how PD-1 inhibitor monotherapy, when paired with CRT, influenced disease progression metrics. Encouragingly, the addition of PD-1 inhibitors markedly improved progression-free survival (PFS) with a hazard ratio (HR) of 0.40, indicating a 60% reduction in the risk of disease progression or death compared with CRT alone.

Event-free survival (EFS), another important endpoint reflecting the duration patients remained free from disease events such as progression, recurrence, or death, also demonstrated significant improvement. The HR of 0.59 conveyed a substantial benefit, highlighting the potential of immunotherapy to enhance the durability of cancer control in this patient cohort. These findings suggest that immune checkpoint blockade may effectively suppress tumor proliferation and impede the mechanisms leading to cancer recurrence.

Beyond survival metrics, the study evaluated the rates of distant metastasis and locoregional recurrence, two key determinants of clinical outcomes and quality of life. PD-1 inhibitor treatment halved the odds of both metastatic spread (OR: 0.50) and local recurrence (OR: 0.43), underscoring its role in stalling the dissemination and resurgence of tumorous lesions. This dual suppression is particularly pivotal for LA-NPC, where both systemic and localized disease control critically influence patient prognosis.

However, the analysis revealed no significant differences in overall survival (OS), with an HR of 0.83. This finding urges caution, suggesting that while PD-1 inhibitors may delay disease progression and reduce recurrence, whether these advantages translate into prolonged life remains an open question requiring longer follow-up and more extensive data.

Safety constitutes a fundamental determinant of treatment feasibility. Notably, the integration of PD-1 inhibitors correlated with a heightened incidence of immune-related adverse events (IRAEs), with a striking Peto odds ratio of 11.14, reflecting a significantly elevated risk of immune-mediated toxicities. These adverse events, ranging from dermatitis to more severe autoimmune phenomena, pose clinical management challenges and necessitate vigilant monitoring.

Additionally, patients receiving PD-1 blockade experienced a moderate increase in severe (grade ≥3) adverse events (OR: 1.50). The incidence of these high-grade toxicities, which may require treatment modifications or hospitalization, speaks to the delicate balance oncologists must strike between harnessing immune activation and preventing harmful overactivation.

This systematic review thus charts a compelling narrative of promise tempered by caution. PD-1/PD-L1 inhibitors represent a transformative approach, revitalizing the immunotherapeutic arsenal against LA-NPC and addressing critical gaps left by CRT alone. Improved PFS, EFS, and diminished metastasis and recurrence rates portend better disease control, yet the absence of clear OS benefit and surging immune toxicities underscore the complexity of clinical translation.

Given the limited number of trials and participants, the authors emphasize the necessity for further robust investigation. Larger, multicenter RCTs with extended follow-up will be essential to definitively delineate the survival impact and long-term safety profile of PD-1/PD-L1 inhibitors in this nuanced clinical context. Moreover, mechanistic studies unpacking the interplay between immune checkpoint modulation and NPC tumor biology could refine patient selection and optimize therapeutic protocols.

From a broader perspective, these findings invigorate the discourse around integrating immunotherapy into multimodal cancer care. They illustrate the potential of personalized medicine approaches that go beyond the cytotoxic paradigm and leverage the immune system’s inherent power to fight cancer. For LA-NPC patients facing historically poor outcomes due to relapse and metastasis, such innovative modalities offer a glimpse of renewed hope.

Clinicians, researchers, and patients alike are watching closely as the field races to confirm and expand on these early signals. The evolution of PD-1/PD-L1 inhibitors in LA-NPC could herald a paradigm shift, making durable disease remission and improved life expectancy more attainable realities. Until then, the evidence compiled by Liu and colleagues lays the groundwork for this exciting journey — one filled with scientific rigor, clinical promise, and the ever-present undertaking of balancing efficacy with safety.

With the oncology community poised at this critical juncture, collaborative efforts and continued clinical vigilance will be paramount to unlocking the full potential of immunotherapy in nasopharyngeal carcinoma. As new data emerge, they will undoubtedly shape guidelines and therapeutic standards, ultimately striving to transform the lived experiences of patients battling this challenging disease.

In sum, the integration of PD-1/PD-L1 inhibitors with CRT in LA-NPC emerges as a beacon of hope, illuminating a path toward enhanced disease control and altered cancer trajectories. This systematic review and meta-analysis exemplify the rigorous scientific appraisal necessary to propel innovative therapies forward, offering a roadmap for future research and clinical application in the dynamic realm of cancer treatment.

Subject of Research: Evaluation of PD-1/PD-L1 inhibitors combined with concurrent chemoradiotherapy for treatment of locally advanced nasopharyngeal carcinoma through systematic review and meta-analysis of randomized controlled trials.

Article Title: PD-1/PD-L1 inhibitors for locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis based on randomized controlled trials

Article References:
Liu, X., Shang, Z., Gao, J. et al. PD-1/PD-L1 inhibitors for locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis based on randomized controlled trials. BMC Cancer (2025). https://doi.org/10.1186/s12885-025-15229-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15229-y